Related references
Note: Only part of the references are listed.Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study
Christopher Ma et al.
INFLAMMATORY BOWEL DISEASES (2016)
An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis
David J. Gibson et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus
Brian Bressler et al.
GASTROENTEROLOGY (2015)
Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis
Sanjay K. Murthy et al.
INFLAMMATORY BOWEL DISEASES (2015)
The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study
K. M. Reich et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3
Jean-Frederic Colombel et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: Results from two referral centres
Michael D. Mandel et al.
DIGESTIVE AND LIVER DISEASE (2014)
Adalimumab Therapy Is Associated With Reduced Risk of Hospitalization in Patients With Ulcerative Colitis
Brian G. Feagan et al.
GASTROENTEROLOGY (2014)
Duration of Disease May Predict Response to Infliximab in Pediatric Ulcerative Colitis
Sabina A. V. Mir et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2014)
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy
Rita Monterubbianesi et al.
JOURNAL OF CROHNS & COLITIS (2014)
Severe Disease Activity and Cytomegalovirus Colitis Are Predictive of a Nonresponse to Infliximab in Patients with Ulcerative Colitis
Sang Hyoung Park et al.
DIGESTIVE DISEASES AND SCIENCES (2013)
Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease
S. Schreiber et al.
JOURNAL OF CROHNS & COLITIS (2013)
Decreasing Colectomy Rates for Ulcerative Colitis: A Population-Based Time Trend Study
Gilaad G. Kaplan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
The Epidemiology of Colectomy in Ulcerative Colitis: Results From a Population-Based Cohort
Laura E. Targownik et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Inflammatory bowel disease: A Canadian burden of illness review
Angela Rocchi et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2012)
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Ingrid Ordas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Decreasing Risk of Colorectal Cancer in Patients With Inflammatory Bowel Disease Over 30 Years
Tine Jess et al.
GASTROENTEROLOGY (2012)
Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease
Stephan R. Vavricka et al.
INFLAMMATORY BOWEL DISEASES (2012)
Postoperative Complications and Mortality Following Colectomy for Ulcerative Colitis
Shanika de Silva et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
Jean Frederic Colombel et al.
GASTROENTEROLOGY (2011)
Current misunderstandings in the management of ulcerative colitis
Thomas Ochsenkuhn et al.
GUT (2011)
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
Walter Reinisch et al.
GUT (2011)
A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization
Abderrahim Oussalah et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
William J. Sandborn et al.
GASTROENTEROLOGY (2009)
Increased Efficacy of Delayed-Release Mesalamine 4.8g/D (800mg Tablet) in Patients Previously Diagnosed with Ulcerative Colitis (UC)
William J. Sandborn et al.
GASTROENTEROLOGY (2009)
Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort
Kathrine Frey Froslie et al.
GASTROENTEROLOGY (2007)
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
J. Satsangi et al.
GUT (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis:: A randomized, placebo-controlled study
G Järnerot et al.
GASTROENTEROLOGY (2005)
Share Paper
